Cullinan Therapeutics Inc (CGEM)
15.30
-0.49
(-3.10%)
USD |
NASDAQ |
Nov 14, 16:00
15.31
+0.01
(+0.07%)
After-Hours: 20:00
Cullinan Therapeutics Enterprise Value: 252.96M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 252.96M |
| November 12, 2024 | 266.29M |
| November 11, 2024 | 338.76M |
| November 08, 2024 | 266.29M |
| November 07, 2024 | 240.78M |
| November 06, 2024 | 292.96M |
| November 05, 2024 | 263.97M |
| November 04, 2024 | 260.49M |
| November 01, 2024 | 252.38M |
| October 31, 2024 | 239.04M |
| October 30, 2024 | 277.89M |
| October 29, 2024 | 318.47M |
| October 28, 2024 | 273.83M |
| October 25, 2024 | 262.81M |
| October 24, 2024 | 257.01M |
| October 23, 2024 | 242.52M |
| October 22, 2024 | 262.23M |
| October 21, 2024 | 276.73M |
| October 18, 2024 | 309.77M |
| October 17, 2024 | 344.56M |
| October 16, 2024 | 358.47M |
| October 15, 2024 | 279.04M |
| October 14, 2024 | 278.47M |
| October 11, 2024 | 277.89M |
| October 10, 2024 | 257.59M |
| Date | Value |
|---|---|
| October 09, 2024 | 233.24M |
| October 08, 2024 | 271.51M |
| October 07, 2024 | 267.45M |
| October 04, 2024 | 284.84M |
| October 03, 2024 | 270.93M |
| October 02, 2024 | 293.54M |
| October 01, 2024 | 309.19M |
| September 30, 2024 | 308.03M |
| September 27, 2024 | 334.12M |
| September 26, 2024 | 340.50M |
| September 25, 2024 | 284.84M |
| September 24, 2024 | 360.79M |
| September 23, 2024 | 301.66M |
| September 20, 2024 | 389.78M |
| September 19, 2024 | 377.61M |
| September 18, 2024 | 336.44M |
| September 17, 2024 | 337.02M |
| September 16, 2024 | 319.05M |
| September 13, 2024 | 378.18M |
| September 12, 2024 | 359.05M |
| September 11, 2024 | 379.92M |
| September 10, 2024 | 370.65M |
| September 09, 2024 | 395.58M |
| September 06, 2024 | 379.92M |
| September 05, 2024 | 377.03M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-131.04M
Minimum
Dec 27 2022
2.116B
Maximum
Mar 10 2021
357.70M
Average
262.23M
Median
Oct 22 2024
Enterprise Value Benchmarks
| CEL-SCI Corp | 38.36M |
| AIM ImmunoTech Inc | 7.900M |
| IGC Pharma Inc | 26.09M |
| NovaBay Pharmaceuticals Inc | 3.432M |
| Protalix BioTherapeutics Inc | 66.58M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -42.03M |
| Total Expenses (Quarterly) | 50.03M |
| EPS Diluted (Quarterly) | -0.75 |
| Earnings Yield | -20.00% |